SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (413)5/31/2005 1:32:04 PM
From: rkrw  Read Replies (2) of 523
 
Comparison NRGN to RNVS deal. Fairly comparable.

Upfront nrgn $30M (even split cash/equity); rnvs $10M
Funding: nrgn $12M over 2 years; rnvs $7M over 2 years
Option to extend: nrgn 3 years; rnvs: 2 years
Potential milestones: nrgn $118M for single indication; rnvs: $170M per product

For both deals bio and pharma combine their VR1 efforts. Both deals big pharma fully funds.

And rnvs is down almost $4 bucks, go figure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News